Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAN106

            Therapeutic Area: Hematology Product Name: CAN106

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: WuXi Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2021

            Details:

            CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 and is intended to prevent the formation of membrane attack complexes on red blood cell surfaces, thereby reducing cell lysis and other symptoms associated with PNH.